Assessment of effects of treatment in individual patients with Alzheimer's disease;Evaluatie van therapie-effecten bij individuele patiënten met de ziekte van alzheimer

Nederlands Tijdschrift voor Geneeskunde

Volumn 145, Issue 8, 2001, Pages 340-345

  Richard, E ^a   Lemstra, A W ^a   Walstra, G J M ^a   Van Gool, W A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; COGNITION; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG INDICATION; HUMAN; MEDICAL DECISION MAKING;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CARBAMATES; COGNITION; HUMANS; NETHERLANDS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PRACTICE GUIDELINES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 0035941772     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Waardebepaling van geneesmiddelen: Werkzaamheid, toepasbaarheid, doeltreffendheid en doelmatigheid
2. Metrifonate for Alzheimer's disease. Is the next cholinesterase inhibitor batter?
3. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
4. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
5. Cholinesteraseremmers bij de ziekte van Alzheimer: Voorlopige aanbevelingen veer de praktijk
6. A review and commentary on a sample of 15 UK guidelines for the drug treatment of Alzheimer's disease
7. Guidelines on drug treatments for Alzheimer's disease
8. Drug treatments for Alzheimer's disease
9. Efficacy of donepezil in Alzheimer's disease: Fact or artefact?
10. Her effect van rivastigmine bij de zickte van Alzheimer
11. Variability in annual mini-mental stale examination score in patients with probable Alzheimer disease: A clinical perspective of data from the consortium to establish a registry for Alzheimer's disease
12. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration
13. Case studies, single-subject research, and N of I randomizcd trials: Comparisons and contrasts
14. Randomised study of n of 1 trials versus standard practice
15. The n-of-1 randomized controlled trial: Clinical usefulness. Our three-year experience
16. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician
17. Repeated exposure to the mini-mental state examination and the information-memory-concentration test results in a practice effect in Alzheimer's disease
18. Meten van her dagelijks functioneren van thuiswonende dementiepatiënten: Ontwikkeling van een vragenlijst
19. Assessment of behavioral problems in dementia: The revised memory and behavior problems checklist
20. Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors
21. Reversible dementia in elderly patients referred to a memory clinic
22. 12
23. A simple test of copying ability and sex define survival in patients with early Alzheimer's disease
24. Use of goal attainment scaling to measure treatment effects in an anti-dementia drug trial
25. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment